Joint Effort to Promote Circulatory Enhancer

(Burlington, MA, SA) and ResQSystems, Inc. (Eden Prairie, MN, USA).

The circulatory enhancer, ResQPOD, has been shown in clinical trials to improve circulation and increase blood flow to vital organs during the administration of cardiopulmonary resuscitation (CPR). Specifically, the enhancer increases blood flow to the heart and brain during CPR, which extends the window of opportunity for survival and improves a patient's chance for complete neurologic recovery.

In accordance with a distribution agreement made by the two companies, Zoll has made a US$1.25 million equity investment in ResQSystems to be used for additional clinical studies and to support worldwide marketing efforts. In return, Zoll has exclusive rights to distribute the device in Europe, Canada, and the United States. The agreement is for five years.

"The addition of the REsQPOD to our product line is an important step forward in helping medical personnel and trained rescuers save the lives of victims of sudden cardiac arrest,” said Richard A. Packer, president and CEO of Zoll. "ResQSystems is an innovative company with a very solid foundation of clinical expertise in cardiac resuscitation.”




Related Links:
Zoll
ResQSystems